Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 671 across all filing types
Latest filing 2020-12-28 Regulatory Filings
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Pursuant to the provisions of Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s Code of Conduct for Prevention of Insider Trading, regarding intimation ....
Regulatory Filings Classification · 95% confidence The document is a notice from Fermenta Biotech Limited regarding the closure of the trading window as per SEBI (Prohibition of Insider Trading) Regulations, 2015. It informs about the trading restrictions around the declaration of quarterly financial results but does not contain any financial data, results, or detailed report. It is a regulatory announcement related to insider trading compliance and trading restrictions, not a financial report or earnings release. The document is relatively short (4621 characters) and serves as a formal notification to the stock exchange and public. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-28 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about scheduled meetings with analysts and institutional investors. It references an earnings presentation for Q2 of FY 2020-21 that has been uploaded on the company's website and the exchange website. The document itself does not contain financial data or the earnings presentation but only announces the schedule and availability of the presentation. It is submitted pursuant to SEBI Listing Obligations and Disclosure Requirements, Regulation 30, which relates to disclosure of material events. The document length is only 2104 characters, indicating it is a brief announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement about a report (earnings presentation) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2020-12-22 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about a scheduled meeting with analysts and institutional investors. It references an "Earnings Presentation for Quarter 2 of Financial year 2020-21" that has been uploaded on the company's website and the exchange website. The document itself does not contain the earnings presentation or detailed financial data, but rather announces the schedule and availability of the presentation. The length is only 2069 characters, which is quite short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement about a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2020-12-17 English
Further to our BSE intimations dated December 03, 2020 regarding - (i) acquisition of 52% stake by Fermenta Biotech Limited's wholly owned subsidiary Fermenta Biotech USA, LLC in AGD Nutrition, ....
Capital/Financing Update Classification · 95% confidence The document is a notification to the stock exchange (BSE Limited) about the name change of a subsidiary company following an acquisition of a majority stake. It includes a press release detailing the acquisition and the renaming of AGD Nutrition LLC to Fermenta USA LLC. There are no financial statements, detailed financial performance data, or management discussion of results. The document is an announcement of a corporate event related to acquisition and name change, not a full merger filing or detailed M&A documentation. It is not a report or financial statement but an update on corporate structure and ownership. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to acquisition and ownership change announcements.
2020-12-15 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Regulatory Filings Classification · 95% confidence The document is a short notice (2100 characters) informing about scheduled meetings with analysts and institutional investors regarding an earnings presentation for Q2 of FY 2020-21. It states that the earnings presentation has been uploaded on the company's website and BSE website, indicating that the actual financial report is not included here but referenced. The document is an intimation or announcement about the schedule of investor meetings and the availability of the earnings presentation, not the earnings release itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement under SEBI Listing Obligations and Disclosure Requirements, and not the actual earnings release or detailed financial report.
2020-12-14 English
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be interacting ....
Investor Presentation Classification · 95% confidence The document is a short notice informing about a scheduled meeting with analysts and institutional investors regarding the Earnings Presentation for Q2 of FY 2020-21. It states that the presentation has been uploaded on the company's website and BSE website. The document does not contain the earnings presentation itself or detailed financial data, but rather an announcement of the meeting and availability of the presentation. The document length is only 2067 characters, which is short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this is an announcement related to an investor presentation, not the presentation itself. Hence, the appropriate classification is Investor Presentation (IP).
2020-12-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.